Dialysis News and Research

Latest Dialysis News and Research

First Edition: July 22, 2013

Today's headlines include reports about the continuing efforts in opposition to the health law as well as a Washington Post investigation into a "flaw" in U.S. health care pricing.

22 Jul 2013

DaVita acquires dialysis operations of Malaysia's CDC Group

DaVita®, a division of DaVita HealthCare Partners Inc. and a leading provider of kidney care services, today announced the acquisition of the dialysis operations of Malaysia's Caring Dialysis Centre Group by DVA (Malaysia) Sdn Bhd.

22 Jul 2013

ACC report helps clinicians optimize appropriate use of noninvasive vascular tests

A new report issued today by the American College of Cardiology (ACC) and developed in collaboration with 10 other leading professional societies provides detailed criteria to help clinicians optimize the appropriate use of certain noninvasive vascular tests when caring for patients with known or suspected disorders of the venous (veins) system.

20 Jul 2013

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for fenofibric acid EQ 45 mg and EQ 135 mg delayed-release capsules.

19 Jul 2013

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene Corporation today announced that after consultation with the U.S. Food and Drug Administration Celgene will discontinue treatment with REVLIMID (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries.

18 Jul 2013

Healthcare system factors may play a role in racial disparities related to kidney failure

Among patients with kidney disease who received specialized pre-dialysis care in a universal healthcare system, blacks experienced faster disease progression than whites, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN). The findings suggest that healthcare system factors have less influence on black-white disparities in kidney function decline than other factors.

12 Jul 2013

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that its phase III study (MM-020/IFM 07-01) of REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival.

11 Jul 2013

Heart transplant could get a second chance to save life

Human hearts which are not used each year because they are deemed unsuitable for an organ transplant could get a second chance to save a life, with the help of new research taking place in the North East.

11 Jul 2013

Middle East respiratory syndrome coronavirus currently unlikely to cause a pandemic, finds study

New estimates of the transmissibility of the Middle East respiratory syndrome coronavirus (MERS-CoV) in humans suggest that it does not yet have pandemic potential, according to research published in The Lancet.

9 Jul 2013

Proposal to cut Medicare ESRD Program may have unintended consequences for people on dialysis

A proposal to cut the Medicare End-Stage Renal Disease (ESRD) Program by nearly 10% may have unintended consequences for people on dialysis. "More than 20 million Americans have kidney disease, and the Medicare ESRD program provides lifesaving care to nearly 400,000 beneficiaries with kidney failure," said Bruce A. Molitoris, MD, FASN, President of the American Society of Nephrology (ASN).

9 Jul 2013

Study examines the best type of dialysis access for elderly patients

Elderly patients with kidney failure may not gain the same benefits from what's considered the gold standard for accessing the blood for dialysis compared with younger patients, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology.

28 Jun 2013

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA- (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia (low blood sugar), and with weight loss instead of weight gain.

24 Jun 2013

Administering large iron doses over short period of time increases patients' risk of infections

While intravenous iron is critical for maintaining the health of many dialysis patients, administering large doses over a short period of time increases patients' risk of developing serious infections, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). Smaller doses given for a longer period of time appears to be much safer.

24 Jun 2013

African-Americans with Medicaid are less likely to receive LKT than patients with private insurance

African-Americans with Medicaid as their primary insurance were less likely to receive a living kidney transplant (LKT) than patients with private insurance, according to a new study by researchers at Wake Forest Baptist Medical Center.

21 Jun 2013

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced top line results of the Phase 4 SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin).

20 Jun 2013

European Commission amends marketing authorisation for Celgene's REVLIMID

Celgene International Sàrl was today notified that the European Commission has amended the marketing authorisation for REVLIMID. This decision means that REVLIMID is now approved to treat patients with transfusion-dependent anaemia due to low or intermediate-1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.

17 Jun 2013

American Ambulance continues to grow and expand in New England region

American Ambulance Service-New England, the premier New England-based provider of emergent and non-emergent ambulance services at both the basic and advanced life support levels, today announced its continued growth and expansion in the New England region.

15 Jun 2013

Teleflex gets FDA clearance to market ARROW NextStep Retrograde Femoral Length Dialysis Catheters

Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, has announced it has received FDA 510(k) clearance to market its ARROW NextStep Retrograde Femoral Length Dialysis Catheters.

11 Jun 2013

Whitehead Institute researchers identify drug target for anemia

Researchers at Whitehead Institute have identified a protein that is the target of glucocorticoids, the drugs that are used to increase red blood cell production in patients with certain types of anemia, including those resulting from trauma, sepsis, malaria, kidney dialysis, and chemotherapy.

10 Jun 2013

Doctors create bioengineered blood vessel and implant it in the arm of kidney disease patient

In a first-of-its-kind operation in the United States, a team of doctors at Duke University Hospital helped create a bioengineered blood vessel and implanted it into the arm of a patient with end-stage kidney disease.

7 Jun 2013

Dialysis News and Research

Latest Dialysis News and Research

First Edition: July 22, 2013

DaVita acquires dialysis operations of Malaysia's CDC Group

ACC report helps clinicians optimize appropriate use of noninvasive vascular tests

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Healthcare system factors may play a role in racial disparities related to kidney failure

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Heart transplant could get a second chance to save life

Middle East respiratory syndrome coronavirus currently unlikely to cause a pandemic, finds study

Proposal to cut Medicare ESRD Program may have unintended consequences for people on dialysis

Study examines the best type of dialysis access for elderly patients

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Administering large iron doses over short period of time increases patients' risk of infections

African-Americans with Medicaid are less likely to receive LKT than patients with private insurance

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

European Commission amends marketing authorisation for Celgene's REVLIMID

American Ambulance continues to grow and expand in New England region

Teleflex gets FDA clearance to market ARROW NextStep Retrograde Femoral Length Dialysis Catheters

Whitehead Institute researchers identify drug target for anemia

Doctors create bioengineered blood vessel and implant it in the arm of kidney disease patient

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Dialysis News and Research

Latest Dialysis News and Research

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Newsletters you may be interested in